Epidemiology of Snakebites for a Large Poison Center from 2007 - 2017

Mitchell Shellman, MS4, Nicklaus Brandeshoff, MD
Department of Emergency Medicine, University of Colorado School of Medicine, Denver, CO
Rocky Mountain Poison and Drug Center, Denver, CO

Background

- Globally, snakebites are a large burden of morbidity and mortality, yet represent a neglected tropical disease with studies being limited in size and scope.
- Understanding the epidemiology of snakebites can help identify at-risk populations, guide public health measures, and determine what bites require medical treatment with antivenom.
- Crofab, the name of the antivenom administered in the USA, has been shown to be very effective in treating severe snakebite cases.
- Snakes are regional with envenomation following local species, yet Crofab covers all major species of snakes without regard to regional incidence.

Methods

- Specialists in Poison Information record data from callisto Rocky Mountain Poison and Drug Center from January 1, 2007 through December 31, 2017 based on standardized protocols.
- Data reviewed and entered into REDCap database.
- Descriptive statistical review of data, pending formal statistical review.

Results

- Fewer snakebites are intentional than compared with previous studies.
- Hands and legs are the most common areas for snakebites to occur.
- Most venomous snakebites result from rattlesnakes and occur in the Western USA.
- Local symptoms occur in 77% of patients, with only 23% experiencing systemic effects and 5% experiencing hematologic changes in laboratory studies.
- Crofab was administered to 48% of all patients bitten by venomous snakes with 65% of rattlesnake bites being administered Crofab, compared to 83% of Crofab administration reported in previous studies.

Discussion

Compared to previous studies, we demonstrate a greater number of unintentional snakebite exposures and an overall lower incidence of Crofab administration over the course of snakebite treatment. Given the incidence of systemic and hematologic symptoms though, Crofab continues to be overused in current treatment algorithms. Given the preponderance of rattlesnake and coral snake bites compared to other species, targeted treatments would appear to be more effective and could reduce the cost of treatment.

References